Prosecution Insights
Prosecution Insights
Tech Center 3900 • Art Units: 1618 3991
This examiner grants 68% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17630286 | CELL PENETRATING PEPTIDE FUNCTIONALIZED PERFLUOROCARBON NANOEMULSION COMPOSITIONS AND METHODS FOR IMAGING CELL POPULATIONS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17844456 | CYCLIC PEPTIDES AS PROTEIN TARGETING AGENTS | Non-Final OA | California Institute of Technology |
| 17770464 | COMPOSITIONS COMPRISING MODIFIED SMARCB1 AND USES THEREOF | Final Rejection | Dana-Farber Cancer Institute, Inc. |
| 17730130 | REAGENTS AND METHODS FOR LABELING MOLECULES WITH ASTATINE ISOTOPES IN HIGHER OXIDATION STATES | Non-Final OA | University of Washington |
| 18041470 | TEXAPHYRIN DERIVATIVES FOR MANGANESE CHEMOTHERAPY, PHOTOACOUSTIC IMAGING, AND PHOTOTHERMAL THERAPY | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17782147 | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | Non-Final OA | Board of Regents, The University of Texas System |
| 17663133 | LUNG TARGETED ANTICANCER THERAPIES WITH LIPOSOMAL ANNAMYCIN | Final Rejection | Board of Regents, The University of Texas System |
| 18036579 | PROBES, SYSTEMS, AND METHODS FOR MAGNETIC RESONANCE PH SENSING | Non-Final OA | The General Hospital Corporation |
| 18676138 | PRE-TARGETING STRATEGIES FOR MOLECULAR IMAGING AND/OR RADIOIMMUNOTHERAPY | Final Rejection | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION |
| 17782908 | INFLAMMATION-RESPONSIVE ANTI-INFLAMMATORY HYDROGELS | Non-Final OA | Nanyang Technological University |
| 17628497 | PARTICLE-BASED METHOD FOR DEFINING A GUT MICROBIOTA IN HUMANS OR OTHER ANIMAL SPECIES | Non-Final OA | Washington University |
| 18773055 | Radiolabeled GRPR-Antagonists for Diagnostic Imaging and Treatment of GRPR-Positive Cancer | Non-Final OA | Advanced Accelerator Applications International SA |
| 18350268 | TOPICAL APPLICATION OF NERVE LABELING DYES FOR IMAGE-GUIDED SURGERY | Non-Final OA | EDISON INNOVATION, LLC |
| 17604708 | NOVEL RADIOLABELLED CXCR4-TARGETING COMPOUNDS FOR DIAGNOSIS AND THERAPY | Final Rejection | THE UNIVERSITY OF BRITISH COLUMBIA |
| 18689166 | ATHEROSCLEROSIS-TARGETED LIPOSOME NANOCARRIER DELIVERY SYSTEM AND PREPARATION METHOD THEREFOR | Non-Final OA | Beijing Inno Medicine Co., Ltd. |
| 17633610 | USE OF FLUOROPHORE COMPOUNDS OF THE AZA- BODIPY TYPE AS CONTRAST AGENTS IN THE SHORT WAVE INFRARED REGION | Non-Final OA | INSERM - Institut National de la Santé et de la Recherche Médicale |
| 17627805 | ANTI-INFECTION EFFECTS OF HNRNPA2B1 AND USE THEREOF | Non-Final OA | INSTITUTE OF BASIC MEDICAL SCIENCES, CHINESE ACADEMY OF MEDICAL SCIENCES |
| 18041532 | COMPOUNDS AND COMPOSITIONS FOR TUMOR DETECTION AND SURGICAL GUIDANCE | Non-Final OA | Molecular Targeting Technologies, Inc. |
| 17786768 | ANTI-HER2 POLYPEPTIDES DERIVATIVES AS NEW DIAGNOSTIC MOLECULAR PROBES | Non-Final OA | BRACCO IMAGING S.P.A. |
| 17789398 | RADIOLABELED PEPTIDES FOR NON-INVASIVE DIAGNOSIS AND TREATMENT OF CXCR4 EXPRESSING TUMORS | Non-Final OA | ISTITUTO NAZIONALE TUMORI IRCCS - FONDAZIONE G. PASCALE |
| 17908262 | NON-ANTIBODY BINDING PEPTIDES AND THEIR ANALOGS DUAL-TARGETING TO PD-1 AND PD-L1, AND USES THEREOF | Non-Final OA | Guangzhou Yidai Pharmaceutical Co., LTD. |
| 17843796 | DRUG DELIVERY SYSTEMS COMPRISING AN INTRAOCULAR PRESSURE LOWERING AGENT, A NEUROTROPHIC AGENT, A C-TYPE NATRIURETIC PEPTIDE, A NATRIURETIC PEPTIDE RECEPTOR-B, AN APOPTOSIS SIGNALING FRAGMENT INHIBITOR OR A FAS-LIGAND INHIBITOR FOR TREATING GLAUCOMA OR OCULAR HYPERTENSION | Non-Final OA | Cella Therapeutics, LLC |
| 17767956 | FIBRIN-BINDING COMPOUNDS FOR IMAGING AND TREATMENT | Final Rejection | Lumina Pharmaceuticals Inc. |
| 17579909 | Method of Treatment of Neuroendocrine Tumors That Over-Express Somatostatatin Receptors | Non-Final OA | ADVANCED ACCELERATOR APPLICATIONS |
| 17618850 | COMPOUNDS AND METHODS OF USE | Final Rejection | EDINBURGH MOLECULAR IMAGING LIMITED |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy